Antibodies News and Research

RSS

Alzheimer's disease found to have five distinct subtypes

Researchers identified five distinct molecular subtypes of Alzheimer's disease using proteomic sequencing, suggesting personalized treatment approaches based on each subtype's unique genetic and pathological characteristics.

10 Jan 2024

Study shows engineered antibodies significantly boost Omicron neutralization

Researchers engineered IgA antibodies from IgG monoclonals, enhancing neutralization against Omicron by up to 75-fold and offering protection in mice models.

10 Jan 2024

Sex-specific blood test could revolutionize early cancer detection for all 18 major cancers

A sex-specific panel of 10 proteins can pick up 18 different early stage cancers, representing all the major organs of the human body, finds a proof of concept study published in the open access journal BMJ Oncology.

10 Jan 2024

New intranasal vaccine candidate triggers powerful mucosal defense against SARS-CoV-2

A team of scientists, led by Duke-NUS Medical School, has discovered a potential intranasal vaccine candidate that provides improved, longer-lasting immunity against SARS-CoV-2 viruses compared to when given as an injection.

10 Jan 2024

Nasal drops with IgA antibodies may protect against COVID-19 and future variants

Researchers at Karolinska Institutet in Sweden have shown that nasal drops with IgA antibodies can protect mice from SARS-CoV-2 infection.

10 Jan 2024

Carvedilol improves heart health marker in childhood cancer survivors

Physicians at City of Hope, one of the largest cancer research and treatment organizations in the United States, in cooperation with the Children's Oncology Group (COG), have conducted the largest clinical trial to date seeking to reduce the risk of people who have survived childhood cancer from developing heart failure.

9 Jan 2024

New Omicron subvariants test vaccine limits, reveal unique infection challenges

Study reveals that the Omicron subvariants BA.2.86 and FLip show unique mutations and infectivity profiles, with BA.2.86 being highly infectious and resistant to most conventional antibodies, underscoring the need for updated vaccines.

9 Jan 2024

New study sheds light on the biological properties of new COVID variant Pirola

Despite the end of the pandemic, COVID-19 continues to pose a serious health threat. Most individuals have established robust immune protection and do not develop severe disease but the infection can still lead to marked and sometimes long-lasting disease symptoms.

9 Jan 2024

Nirmatrelvir treatment shows no link to reduced long-COVID risk, study reveals

Recent study reveals nirmatrelvir treatment during acute COVID-19 does not lower the risk of post-acute COVID-19 symptoms, nor is it associated with symptomatic rebound.

8 Jan 2024

SARS-CoV-2 BA.2.86 shows increased lung targeting despite vaccine effectiveness

New research shows that the recently emerged BA.2.86 omicron subvariant of the virus that causes COVID-19 can be neutralized by bivalent mRNA vaccine-induced antibodies in the blood, which explains why this variant did not cause a widespread surge as previously feared.

8 Jan 2024

There’s a new covid-19 variant and cases are ticking up. What do you need to know?

It's winter, that cozy season that brings crackling fireplaces, indoor gatherings — and a wave of respiratory illness.

8 Jan 2024

Genetic keys to COVID-19 vaccine response unlocked

A genome-wide association study in the U.K. Biobank reveals genetic factors influencing IgG serostatus against SARS-CoV-2, highlighting the role of HLA class II genes in variable immune responses to COVID-19 vaccines.

7 Jan 2024

Researchers identify mechanism that causes gastrointestinal problems with cancer immunotherapy

Researchers at the University of Michigan Health Rogel Cancer Center have identified a mechanism that causes severe gastrointestinal problems with immune-based cancer treatment.

5 Jan 2024

Stapled lipopeptides show promise as broad-spectrum antiviral agents

Compounds that obstruct the "landing gear" of a range of harmful viruses can successfully protect against infection by the virus that causes COVID-19, a study published today and led by Dana-Farber Cancer Institute scientists shows.

5 Jan 2024

Anti-CTLA-4 nanobodies offer promising strategy to prevent colitis in cancer immunotherapy

Microbiota-reactive T cells trigger colitis in mice harboring the microbiota of wild-caught mice following CTLA-4 blockade, according to a new study that reveals a major mechanism by which anti-CTLA-4 antibodies induce inflammatory toxicities during antitumor immune checkpoint inhibitor therapies.

4 Jan 2024